EcoR1 Capital LLC Buys Shares of 5,025 Forward Pharma A/S (FWP)

EcoR1 Capital LLC bought a new stake in shares of Forward Pharma A/S (NASDAQ:FWP) during the first quarter, Holdings Channel reports. The institutional investor bought 5,025 shares of the biotechnology company’s stock, valued at approximately $108,000.

A number of other large investors have also recently modified their holdings of the stock. Citadel Advisors LLC bought a new stake in shares of Forward Pharma A/S during the first quarter valued at about $269,000. Morgan Stanley increased its stake in shares of Forward Pharma A/S by 57.4% in the first quarter. Morgan Stanley now owns 33,289 shares of the biotechnology company’s stock valued at $716,000 after buying an additional 12,142 shares during the period. Marshall Wace North America L.P. bought a new stake in shares of Forward Pharma A/S during the first quarter valued at about $612,000. MARSHALL WACE ASIA Ltd bought a new stake in shares of Forward Pharma A/S during the first quarter valued at about $612,000. Finally, Eqis Capital Management Inc. bought a new stake in shares of Forward Pharma A/S during the first quarter valued at about $346,000. Institutional investors and hedge funds own 22.24% of the company’s stock.

Institutional Ownership by Quarter for Forward Pharma A/S (NASDAQ:FWP)

Shares of Forward Pharma A/S (NASDAQ FWP) traded up 8.18% on Friday, hitting $21.96. 70,493 shares of the stock traded hands. The stock’s market cap is $1.04 billion. Forward Pharma A/S has a 52 week low of $14.89 and a 52 week high of $33.00. The stock has a 50 day moving average price of $19.66 and a 200-day moving average price of $22.41.

ILLEGAL ACTIVITY NOTICE: This story was first reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://sleekmoney.com/ecor1-capital-llc-buys-shares-of-5025-forward-pharma-as-fwp/1916426.html.

Several equities research analysts have issued reports on FWP shares. Zacks Investment Research downgraded shares of Forward Pharma A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, March 21st. Jefferies Group LLC reaffirmed a “hold” rating and set a $41.00 target price on shares of Forward Pharma A/S in a report on Friday, March 31st. Leerink Swann set a $28.00 target price on shares of Forward Pharma A/S and gave the stock a “buy” rating in a report on Monday, April 3rd. Finally, JMP Securities cut shares of Forward Pharma A/S from an “outperform” rating to a “market perform” rating in a report on Monday, April 3rd.

Forward Pharma A/S Company Profile

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.

Want to see what other hedge funds are holding FWP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Forward Pharma A/S (NASDAQ:FWP).

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/ecor1-capital-llc-buys-shares-of-5025-forward-pharma-as-fwp/1916426.html

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *